<SEC-DOCUMENT>0001213900-22-037747.txt : 20220707
<SEC-HEADER>0001213900-22-037747.hdr.sgml : 20220707
<ACCEPTANCE-DATETIME>20220707074931
ACCESSION NUMBER:		0001213900-22-037747
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220707
FILED AS OF DATE:		20220707
DATE AS OF CHANGE:		20220707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		221070648

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea162566-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of July 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Report No. 2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): &nbsp;__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): &nbsp;__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">On July 6, 2022,
SciSparc Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc Board of Directors to Promote Buyback Program
of up to $1 Million&rdquo;, a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report on Form 6-K is
incorporated by reference into the registration statements on Form F-3 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016952/ff32019a1_therapixbio.htm">333-233417</A> and File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A>) and on Form S-8 (File
No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>) of the Company, filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea162566ex99-1_scisparc.htm">Press release dated July 6, 2022, titled &ldquo;SciSparc Board of Directors to Promote Buyback Program of up to $1 Million&rdquo;.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: July 7, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 32%"> <FONT STYLE="font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer &amp;<BR>
 Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea162566ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE DATED JULY 6, 2022, TITLED "SCISPARC BOARD OF DIRECTORS TO PROMOTE BUYBACK PROGRAM OF UP TO $1 MILLION"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SciSparc Board of Directors to Promote Buyback
Program of up to $1 Million </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TEL AVIV, Israel, July 6, 2022 /PRNewswire/ -- SciSparc
Ltd. (Nasdaq: SPRC) (the &ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), a specialty, clinical-stage pharmaceutical company focusing on
the development of therapies to treat disorders of the central nervous system, today announced its board of directors authorized the Company
to take actions to implement a $1 million buyback program for the Company&rsquo;s ordinary shares, no par value (the &ldquo;Ordinary Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to formally approve the buyback
in conjunction with the approval of its financial statements for the 6 months ended June 30, 2022, together with a financial advisor&rsquo;s
opinion to be obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is required to file a motion seeking
a court approval in Israel for the buyback program, and the effectiveness of the buyback plan, if formally approved, will be contingent
upon such court&rsquo;s approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About SciSparc Ltd. (Nasdaq: SPRC):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s focus is on creating and enhancing a portfolio
of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome, for the treatment
of Alzheimer&rsquo;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and
status epilepticus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B>:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within the
meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking statements when it discusses the contemplated buyback
program&nbsp;as there is no assurance that any of the conditions required by law for the effectiveness of the program will be
satisfied and accordingly whether the buyback program will be initiated&nbsp;or its timing. Because such statements deal with future
events and are based on SciSparc&rsquo;s current expectations, they are subject to various risks and uncertainties and actual results,
performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press
release. The forward- looking statements contained or implied in this press release are subject to other risks and uncertainties,
including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual Report on Form 20-F filed with the U.S.
Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on April 28, 2022, and in subsequent filings with the SEC. Except as
otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which
speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:<BR>
</B>IR@scisparc.com&nbsp;<BR>
Tel: +972-3-6167055</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !S ',# 2(  A$! Q$!_\0
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MG]HCP!:V5IX\T>*$,;/2O$T$B)8>/?"T1=D70]?#S6:.S:+J6DSDS'^.B_\
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MHES<M96^LW.BI.=2M]*GO%:UAU&6V2TEN5:!)FE4J/AGQ5^PAI_QA_:_TO\
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
